Table 2.
Operative data
| Number | 75 |
| Bio-prosthesis | 73 (97%) |
| Mechanical-prosthesis | 2 (3%) |
| Aortic root enlargement | 1 (1%) |
| Size of prosthesis | |
| 16 mm | 1 (1%) |
| 17 mm | 1 (1%) |
| 19 mm | 26 (35%) |
| 21 mm | 31 (41%) |
| 23 mm | 13 (17%) |
| 25 mm | 3 (4%) |
| Isolated aortic valve replacement | 49 (65%) |
| Concomitant surgery | 26 (35%) |
| CABG | 18 (24%) |
| Mitral valve replacement | 7 (9%) |
| Mitral annuloplasty | 2 (3%) |
| Trisupid annuloplasty | 3 (4%) |
| Asc-Ao replacement | 3 (4%) |
| Maze | 3 (4%) |
| ACCT (min) | 96.9 ± 43.3 |
| ACCT ≥120 min | 16 (21%) |
| ECCT (min) | 147.3 ± 58.3 |
| ECCT ≥180 min | 17 (23%) |
| Dopamine use | 61 (81%) |
| Dobutamine use | 41 (55%) |
| Epinephrine use | 14 (19%) |
| Norepinephrine use | 8 (11%) |
| Carperitide use | 36 (48%) |
Asc-Ao: ascending aorta; CABG: coronary artery bypass grafting; ACCT: aortic cross clamping time; ECCT: extracorporeal circulation time